Friday-Sunday, March 2-4, 2018 — Miami, Florida

The 15th Annual Winter Lung Cancer Conference

Dates:
March 2-4, 2018

Location:
Turnberry Isle Miami
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: (305) 932-6200

Meeting Room:
Grand Ballroom (Lobby Level)
 
 
Note from Moderators:
This coming March will mark the 15th year of the Winter Lung Cancer Conference, and like a fine wine, the event continues to get better with age. Designed to provide thorough, practically oriented reviews of key management issues in this all too prevalent disease, this engaging, one-of-a-kind offering will once again span parts of 3 days and feature a stellar multidisciplinary faculty panel and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. To augment the conference’s interactivity, each clinician will be provided with a specially configured iPad® to use throughout the program to participate in audience polling, view all the presentation slides and anonymously submit questions to the panelists for the aforementioned Q&A. The conference’s educational design and the topics that will be discussed offer interested clinicians the opportunity to access the in-depth perspectives of some of the top minds in the field regarding significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with this challenging disease.

So as you begin to make your plans for 2018, we hope you will join us in sunny South Florida for a lung cancer learning experience unlike any other out there.

Co-Chairs and Moderators
Rogerio C Lilenbaum, MD
Professor of Medicine
Yale School of Medicine
Chief Medical Officer
Smilow Cancer Hospital
Yale Cancer Center
New Haven, Connecticut

Neil Love, MD
Research To Practice
Miami, Florida

Mark A Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
Orlando, Florida

Faculty:
Ethan M Basch, MD, MSc (Keynote)
Professor of Medicine and Public Health
Director, Cancer Outcomes Research Program
Co-Leader, Cancer Prevention and Control
Associate Chief, Division of Oncology
University of North Carolina
Chapel Hill, North Carolina

Jeffrey Crawford, MD
George Barth Geller
Professor for Research in Cancer
Co-Director, Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, North Carolina

Jesse R Fann, MD, MPH
Director, Psychiatry and Psychology Service
Seattle Cancer Care Alliance
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor, Department of Psychiatry and Behavioral Sciences
University of Washington
Seattle, Washington

Leena Gandhi, MD, PhD
Director, Perlmutter Cancer Center
Langone Health
New York University
New York, New York

Edward B Garon, MD, MS
Associate Professor
Director, Thoracic Oncology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

David E Gerber, MD
Associate Professor
Division of Hematology-Oncology
Associate Director for Clinical Research
Co-Leader, Experimental Therapeutics Program
Co-Director, Lung Disease Oriented Team
Harold C Simmons Comprehensive Cancer Center
University of Texas
Southwestern Medical Center
Dallas, Texas

Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Nasser H Hanna, MD
Associate Professor of Medicine
Indiana University
Indianapolis, Indiana

Jennifer M Kapo, MD
Associate Professor of Medicine (Geriatrics)
Chief, Palliative Medicine
Smilow Cancer Hospital
Yale Cancer Center
New Haven, Connecticut

Billy W Loo Jr, MD, PhD, DABR
Associate Professor, Thoracic Radiation Oncology Program Leader
New Technologies Committee Co-Chair
Department of Radiation Oncology
Stanford Cancer Institute
Stanford, California

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Anne S Tsao, MD
Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Douglas E Wood, MD
The Henry N Harkins Professor and Chair
Department of Surgery
University of Washington
Seattle, Washington

 

Friday, March 2nd

6:30 PM – 7:15 PM
Welcome Reception

7:15 PM – 7:45 PM
Keynote Address — Dr Basch
Improving Patient and Physician Communication: Recap of ASCO 2017 Plenary Presentation on Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment and Discussion of How This Research Can Be Applied to Routine Care
If This Were a Drug, Would It Be Approved, and Would We Be Giving It?

7:45 PM – 8:00 PM
Moderated Q&A Session

Moderator: Dr Love

Saturday, March 3rd

NOTE: All conference lectures will employ a traditional didactic format. However, frequently throughout each talk the moderator will interject questions and call on the lead discussant and other panelists to provide additional perspectives. After each talk, the faculty panelists will discuss actual cases from their practices to further explore practical concepts introduced as part of their presentations.

8:00 AM – 9:30 AM
SESSION 1: Management of Non-Small Cell Lung Cancer (NSCLC) with a Targetable Mutation — Part 1 — Drs Gubens, Riely, Sequist and Tsao

Moderator: Dr Love

Presentation 1: Molecular testing in clinical practice: CAP, IASLC and AMP Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer — Dr Tsao

Presentation 2: Front-line treatment for patients with EGFR tumor mutations; results of the FLAURA trial and clinical implications — Dr Riely

Presentation 3: Available data and ongoing trials evaluating adjuvant therapy for patients with EGFR mutations — Dr Gubens

Presentation 4: Selection of first-line therapy for patients with ALK-rearranged or ROS1-positive NSCLC; implications of the ALEX study — Dr Gubens

Clinical issues and topics reviewed during panel and case discussions:

  • Current nonprotocol biomarker assessment algorithms: Role of standard biomarker assays versus multiplex testing/next-generation sequencing
  • Current and emerging role of rapid plasma genotyping to identify patients with targetable mutations at diagnosis and relapse
  • First-line treatment options for patients with EGFR mutation-positive disease; potential implications of the Phase III FLAURA trial results
  • Effect of EGFR variant on the selection of first-line systemic therapy; recent label expansion for the use of afatinib in patients with L861Q, G719X and S768I mutations
  • Incidence, prophylaxis and management of gastrointestinal, dermatologic and other side effects associated with osimertinib
  • Phase III data evaluating gefitinib versus cisplatin/vinorelbine as adjuvant therapy in patients with an EGFR-activating mutation; other available data sets with adjuvant EGFR TKIs
  • Mechanistic similarities and differences among crizotinib, ceritinib, alectinib and brigatinib
  • Selection of first-, second- and later-line therapy for patients with ALK- or ROS1-positive disease; implications of recent data sets and drug approvals

9:30 AM – 9:50 AM
Break

9:50 AM – 11:20 AM
SESSION 2: Management of NSCLC with a Targetable Mutation — Part 2 — Drs Gandhi, Hanna, Riely and Sequist

Moderator: Dr Love

Presentation 5: Identification of and treatment for patients with BRAF V600E mutations and MET mutations/amplifications — Dr Gandhi

Presentation 6: Potential clinical benefits and investigational opportunities associated with the identification of HER2 mutations and RET rearrangements — Dr Hanna

Presentation 7: Optimal management of CNS metastases in patients with a targetable mutation — Dr Riely

Presentation 8: Effectiveness and role of immunotherapy in patients with tumor driver mutations — Dr Sequist

Clinical issues and topics reviewed during panel and case discussions:

  • FDA approval of dabrafenib/trametinib for patients with BRAF V600E-mutant NSCLC
  • Incidence of HER2 mutations/amplification and available data with HER2-targeting agents (eg, trastuzumab, T-DM1, afatinib, neratinib)
  • Preliminary efficacy and safety data with cabozantinib and other targeted agents for RET-rearranged NSCLC
  • Therapeutic selection for patients with MET exon 14 skipping mutations
  • Management of CNS metastases in patients with EGFR mutations; available data with osimertinib in patients with CNS and leptomeningeal disease
  • Variable CNS permeability with approved and investigational ALK inhibitors and implications for the management of ALK/ROS1-positive brain metastases
  • Sequencing immune checkpoint inhibitors for patients with metastatic NSCLC and a documented genomic alteration

11:20 AM – 12:50 PM
SESSION 3: Current and Future Application of Immunotherapy in Lung Cancer — Part 1: NSCLC — Drs Garon, Gubens, Hanna and Socinski

Moderator: Dr Love

Presentation 9: PD-L1, tumor mutation burden and other potential predictors of response to immune checkpoint inhibition in NSCLC — Dr Gubens

Presentation 10: Emerging research data with and potential clinical role of immune checkpoint inhibitors in the management of locally advanced NSCLC — Dr Hanna

Presentation 11: Integration of anti-PD-1/PD-L1 antibodies into current treatment algorithms for patients with metastatic NSCLC — Dr Garon

Presentation 12: Novel immunotherapeutic approaches, including combination strategies; current role of anti-angiogenics in NSCLC — Dr Socinski

Clinical issues and topics reviewed during panel and case discussions:

  • Impact of PD-L1 tumor proportion score (TPS) on responsiveness to anti-PD-1/PD-L1 therapy and implications for therapeutic selection
  • Major efficacy and safety findings from the PACIFIC trial and the potential nonresearch role of sequential durvalumab in the management of Stage III disease
  • Active and planned studies of other immune checkpoint inhibitors in the localized and locally advanced settings
  • Clinical and biologic factors affecting the selection of front-line therapy
  • FDA approval of pembrolizumab in combination with carboplatin/pemetrexed as first-line therapy for patients with metastatic nonsquamous NSCLC regardless of TPS
  • Available data with and current clinical role of anti-PD-1/PD-L1 antibodies as second-line therapy
  • Ongoing clinical trials of anti-PD-1/PD-L1 antibodies in combination with other systemic approaches
  • Rationale for the integration of ramucirumab into the management of nonsquamous and squamous NSCLC; effect, if any, of prior exposure to anti-VEGF or anti-PD-1/PD-L1 therapy on efficacy
  • Current role of bevacizumab in NSCLC

12:50 PM – 1:50 PM
Lunch

1:50 PM – 3:30 PM
SESSION 4: Current and Future Application of Immunotherapy in Lung Cancer — Part 2: Small Cell Lung Cancer (SCLC) and Malignant Pleural Mesothelioma (MPM) — Drs Gandhi, Garon, Lilenbaum and Tsao

Moderator: Dr Love

Presentation 13: Optimal duration of anti-PD-1/PD-L1 therapy for patients experiencing a clinical response; continuation of an immune checkpoint inhibitor upon disease progression — Dr Garon

Presentation 14: Does hyperprogression occur in patients receiving an anti-PD-1/PD-L1 antibody? — Dr Lilenbaum

Presentation 15: Current management and ongoing clinical trials in SCLC, including immunotherapy and antibody-drug conjugates — Dr Gandhi

Presentation 16: Emerging role of immune checkpoint inhibitors and other novel strategies in MPM — Dr Tsao

Clinical issues and topics reviewed during panel and case discussions:

  • Deciphering pseudoprogression versus true disease progression in patients receiving anti-PD-1/PD-L1 therapy; current role of treatment beyond progression
  • Prevalence, natural history and predictive factors of hyperprogressive disease in patients receiving anti-PD-1/PD-L1 therapy
  • Published research findings with anti-PD-1 therapy alone or in combination with an anti-CTLA-4 antibody for recurrent SCLC; ongoing evaluation of combination anti-PD-1 and anti-CTLA-4 therapy for untreated or progressive SCLC
  • Activity of the novel antibody-drug conjugate rovalpituzumab tesirine for relapsed/refractory SCLC
  • PD-L1 expression in MPM; current data with and planned and ongoing clinical trials of immunotherapeutic approaches
  • Other novel agents under investigation in SCLC and MPM

3:30 PM
Adjourn

Sunday, March 4th

8:00 AM – 9:00 AM
SESSION 5: Meet the Professors: Palliative Care and Psychiatric Support for Patients with NSCLC — Drs Fann, Kapo, Lilenbaum and Socinski

Moderator: Dr Love

During each of these modules, an invited faculty member with a particular and specialized research interest will participate in a focused presentation/discussion related to a singular topic. At numerous time points the moderator will call on other panelists and the audience to inject comments and questions. However, the majority of the time will be spent interrogating and learning from the invited expert.

Presentation 1: Palliative care in lung cancer management — New clinical research findings; patterns of care in the community — Dr Kapo

Presentation 2: Update on clinical research on the management of psychiatric/psychologic issues in lung cancer management; case discussions — Dr Fann

9:00 AM – 10:30 AM
SESSION 6: Surgery, Radiation Therapy and Other Issues in the Management of NSCLC —
Drs Crawford, Gerber, Loo and Wood

Moderator: Dr Lilenbaum

Given that the subject matter to be reviewed as part of each presentation is somewhat unique in nature and specific to the expertise of the presenting panelist, each lecture in this module will be accompanied by discussion of actual cases from the practice of the assigned faculty member.

Presentation 3: Radiation therapy: Challenging clinical scenarios and related management issues — Dr Loo

SAMPLE CASE-BASED DISCUSSION TOPICS:

  • Individualized radiation treatment planning
  • Current research on thoracic radiation therapy in Stage III disease

Presentation 4: Update on the surgical management of lung cancer — Dr Wood

SAMPLE CASE-BASED DISCUSSION TOPICS:

  • Unresolved controversies in the surgical management of lung cancer (eg, lobectomy versus stereotactic radiosurgery)
  • Indications for sublobar resection for localized NSCLC

Presentation 5: Optimal management of oligometastatic disease — Dr Crawford

SAMPLE CASE-BASED DISCUSSION TOPICS:

  • Definition, sites and prevalence of oligometastatic disease 
  • Outcomes for patients presenting with de novo and recurrent oligometastatic disease 
  • Treatment options and clinical trial concepts for patients presenting with oligometastatic disease 

Presentation 6: Trials evaluating checkpoint inhibitors and targeted therapy in the adjuvant and neoadjuvant settings — Dr Gerber

SAMPLE CASE-BASED DISCUSSION TOPICS:

  • Ongoing trials evaluating immune checkpoint inhibitors as (neo)adjuvant therapy
  • Available data sets evaluating targeted therapy in the adjuvant setting

10:30 AM – 10:50 AM
Break

10:50 AM – 12:00 PM
SESSION 7: Practical Clinical Issues in the Treatment of Locally Advanced NSCLC in the Current Era — Drs Crawford, Gerber, Loo and Wood

Moderator: Dr Socinski

Presentation 7: Surgical approach in patients with locally advanced disease; neoadjuvant chemotherapy for NSCLC — Dr Wood

Presentation 8: Incidence and management of toxicities in patients with locally advanced disease receiving chemoradiation therapy — Dr Loo

Presentation 9: Management of toxicities associated with immune checkpoint inhibitors in the locally advanced and metastatic settings — Dr Gerber

Presentation 10: Immunotherapy in patients with a history of autoimmune disease or paraneoplastic syndromes in the locally advanced and metastatic settings — Dr Crawford

Clinical issues and topics reviewed during panel and case discussions:

  • Management of immune-related side effects in patients who are receiving a checkpoint inhibitor in the curative setting
  • Utility of consolidation and maintenance treatment for locally advanced disease
  • Prevention, recognition and management of immune-mediated side effects: pneumonitis, endocrinopathies, dermatologic toxicities, gastrointestinal complications, et cetera
  • Threshold for dose reduction, dose interruption or discontinuation for patients experiencing immune-related toxicities
  • Frequency and intensity of immune-related adverse events documented in patients with lung cancer receiving checkpoint inhibitors
  • Effects of immune therapies in patients with prior autoimmune diseases: rheumatoid arthritis, Crohn’s disease, psoriasis, multiple sclerosis, et cetera

12:00 PM
Adjourn

Target Audience:
This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Design evidence-based strategies for the diagnosis and management of Stage I to Stage III non-small cell lung cancer (NSCLC), considering the potential contributions of systemic and/or local therapeutic modalities.
  • Appreciate emerging Phase III data documenting the benefit of sequential anti-PD-L1 therapy after the completion of chemoradiation therapy for patients with Stage III NSCLC, and consider the potential future role of this therapeutic approach.
  • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, select optimal testing platforms and appropriately apply the results to individualize first- and later-line therapy for patients with NSCLC according to their potential response or resistance to a specific treatment.
  • Review published research data documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
  • Consider age, performance status, PD-L1 tumor proportion score and other patient or disease characteristics to guide the selection of induction and maintenance systemic therapy for patients with metastatic NSCLC without an identifiable driver mutation.
  • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
  • Assess new oncogenic pathways mediating the growth of unique tumor subsets, and recall emerging data with with commercially available and experimental agents exploiting these targets.
  • Describe ongoing trials evaluating novel applications of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, anti-PD-1/PD-L1 antibodies in combination with other checkpoint inhibitors, chemotherapy or targeted therapy) for diverse lung cancer variants, and counsel appropriately selected individuals about potential participation.
  • Formulate management strategies for small cell lung cancer, considering the contributory roles of local and systemic therapy in addition to current research studies evaluating novel immunotherapeutic and targeted approaches.
  • Consider the use of multimodality therapy for appropriate patients with mesothelioma who might be cured with this approach, and devise optimal management strategies for those with advanced disease, including the option of clinical trial participation.

Accreditation Statements:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CME Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statement
This educational activity for 10.5 contact hours is provided by Research To Practice.

This activity is awarded 10.5 ANCC pharmacotherapeutic contact hours.

Credit Form:
A credit form will be given to each participant at the conclusion of the activity. To obtain a certificate of completion, please return your CME/CNE Credit Form to the registration desk as you exit the activity. Nurses must also sign in at registration.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

ONCC/ILNA Certification Information:
This program will be submitted for ONCC/ILNA certification.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

Supporters:
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Lilly, Novartis and Takeda Oncology.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Turnberry Isle Miami
19999 West Country Club Drive
Aventura, FL 33180
Hotel Phone: (305) 932-6200

Meeting Room:
Grand Ballroom (Lobby Level)

Room Reservations:
A special discounted room rate of $299 (plus applicable tax & discounted resort fee of $10) is available to conference attendees at the Turnberry Isle Miami hotel. To secure accommodations, please contact the Turnberry Isle Miami directly at (888) 539-7894 or (305) 932-6200. A personal credit card will be required to secure accommodations.

Please mention you are participating in the Winter Lung Cancer Conference to receive the special group rate.

Room reservations must be made by Friday, February 16, 2018. A limited number of rooms are available, and we encourage you to make your reservations early. After February 16, 2018, the hotel will offer the best rates based on room availability.


View Larger Map

Driving Directions:

From Miami International Airport

  • The drive from Miami International Airport takes approximately 35 minutes.
  • Exit the airport and follow the signs to I-95 North.
  • Take I-95 North to Ives Dairy Road, exit 16 (also called NE 203 Street).
  • Go East on Ives Dairy Road to US1 (also called Biscayne Blvd).
  • Turn right on Biscayne Blvd and immediately make first left at the traffic light onto Aventura Blvd (NE 199 Street).
  • Continue to the end and turn right on West Country Club Drive. The resort's main entrance is on your left.

(Please note: There is a $1.25 toll on expressway 112.)

From Fort Lauderdale International Airport

  • The drive from the Fort Lauderdale International Airport takes approximately 20 minutes.
  • Exit the airport and follow signs to I-95 South.
  • Take I-95 South to Ives Dairy Road, exit 16 (also called NE 203 Street).
  • Go East on Ives Dairy Road to US1 (also called Biscayne Blvd).
  • Turn right on Biscayne Blvd and immediately make the first left at the traffic light onto Aventura Blvd (NE 199 Street).
  • Continue to the end and turn right on West Country Club Drive. The resort's main entrance is on your left.

This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.

Registration Fees:
This event is free of charge for practicing physicians, fellows, nurses and other healthcare providers involved in the treatment of lung cancer.

For all other individuals, including industry professionals*, a registration fee of $1,075 is available through February 1, 2018 and then $1,175 after this day. All fees processed will be nonrefundable after January 30, 2018 (5:00 PM Eastern Time). To cancel your registration, please contact our Meeting Services department at Meetings@ResearchToPractice.com or (800) 233-6153.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/ industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.